Investors

M Ventures is a strategic, corporate venture capital fund, with a mandate to invest in innovative technologies and products with the potential to significantly impact the business priorities of Merck KGaA, Darmstadt, Germany. From its headquarters in Amsterdam and offices in Germany, US and Israel, M Ventures invests globally in transformational ideas driven by great entrepreneurs in line with its two investment areas Biotechnology and Technology. M Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success.

For more about M Ventures, visit www.m-ventures.com.

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com.

In addition, to learn more, please visit us on and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Taiho Ventures, LLC is the corporate venture arm of Taiho Pharmaceutical Co., Ltd., a Japanese specialty pharmaceutical company focusing on oncology, allergy and immunology, and urology. With $300M under management, we are actively investing in early-stage innovative companies strategically relevant to Taiho Pharmaceutical. We consider company creation, spinouts and the option-type of investments as well as pure equity investments.

See www.taihoventures.com

Seroba is a European life sciences venture capital firm focused on investing in winning innovations in biotech and medtech. The team has deep investment and industry experience enabling Seroba to help entrepreneurs realise their ambitions whilst creating value for investors. The firm has three funds under management and has built a portfolio of investee companies across multiple indications. Seroba partners with entrepreneurs to create and build businesses around extraordinary science.

Follow our story at seroba-lifesciences.com

Cambridge Innovation Capital (CIC) is a leading venture investor backing and building category-leading deep tech and life sciences companies. CIC was founded to improve the success rate of businesses originating from the University of Cambridge and the broader Cambridge ecosystem, to encourage more academics and entrepreneurs from the area to build businesses. CIC currently manages in excess of £0.5 billion and has invested in around 40 companies. CIC is a preferred investor for the University of Cambridge, Europe’s top source of founders for venture-backed start-ups. Cambridge Innovation Capital Manager Limited (FRN:918898) is authorised and regulated by the Financial Conduct Authority.

For more information, please visit www.cic.vc.

IP Group develops world-changing science and technology businesses across life sciences, technology and cleantech (through Kiko Ventures). The Group has a strong track record of success, having been the founder investor in a number of high-profile companies including Oxford Nanopore Technologies plc, and has one of the most exciting portfolios of high-growth businesses in Europe. The Group also owns Parkwalk, the UK's largest growth EIS fund manager which backs world-changing technologies emerging from the UK’s leading universities and research institutions. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

For more information, please visit our website at www.ipgroupplc.com.

The University of Tokyo IPC is a company responsible for expanding the innovation ecosystem of the University of Tokyo. Accelerate global innovation from the University of Tokyo through three activities: start-up support, investment business, and corporate innovation support.

For further information, please visit www.utokyo-ipc.co.jp/en/

Fast Track Initiative is a biotech-focused venture capital firm that has offices in Tokyo and Boston. We find out, invest, and grow transformative early-stage companies across healthcare sectors. Over 15 years of investment experience, we have managed a total of $100M and grown 20+ innovative companies.

For further information, please visit www.fti-jp.com/en/